| [1] |
Torre LA, Bray F, Siegel RL , et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
|
| [2] |
Llovet J M, Ducreux M, Lencioni R , et al. European Association For The Study O f The Liver European O rganisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012,56(4):908-943.
|
| [3] |
Cheng S, Chen M, Cai J , et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition[J]. Oncotarget, 2017,8(5):8867-8876.
|
| [4] |
Zhang YF, Guo RP, Zou RH , et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol, 2016,26(7):2078-2088.
|
| [5] |
Gao S, Zhang PJ, Guo JH , et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients[J]. World J Gastroenterol, 2015 , 21(36):10443-10452.
|
| [6] |
He MK, Le Y, Li QJ , et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer ( 2017) 36:83.
|
| [7] |
Lyu N, Kong Y, Mu L , et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. Journal of Hepatology, 2018,69(1):60-69
|
| [8] |
Norihiro K, Nobuyuki T, Kiyoshi H , et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines)2019 update[J]. Hepatology Research, 2019 , 49(10):1109-1113
|
| [9] |
刘影, 张跃伟, 郭志 . 微粒TACE治疗肝癌伴富血供门静脉癌栓的初步临床经验[J]. 中华医学杂志, 2014,94(7):549-551.
|
| [10] |
张跃伟, 刘影, 任志忠, 岳元勋, 韩东冬 . 微粒-TACE同步治疗肝癌伴Ⅲ型门静脉癌栓6例[J]. 介入放射学杂志, 2018,27(12):1186-1189
|
| [11] |
Zhou J, Liu Y, Ren Z, Zhang Y*, Zhang M. T . ransarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience[J]. J Cancer Res Ther , 2017,13(5):767-772.
|
| [12] |
He MK, Zou RH, Li QJ , et al. Phase Ⅱ study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5 - fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018,41:734-743.
|
| [13] |
Zhu K, Chen J, Lai L , et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study[J]. Radiology, 2014,272(1):284-293.
|
| [14] |
刘广宇, 刘影, 张跃伟 . TACE联合索拉非尼治疗中晚期肝细胞肝癌疗效及安全性初步评价[J]. 肝癌电子杂志, 2018,5(02):19-23.
|
| [15] |
Kokudo T, Hasegawa K, Matsuyama Y , et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion[J]. J Hepatol, 2016,65(5):938– 943.
|
| [16] |
Peng ZW, Guo RP, Zhang YJ , et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer, 2012,118(19) : 4725-4736.
|
| [17] |
Li N, Feng S, Xue J , et al. Hepatocellular carcinoma with main portal vein tumor thrombus: A comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB(Oxford) , 2016,18(6) : 549-556.
|
